Iodine-131 Therapy and the Dialysis Patient M.J. Bohan and R.L. Richardson Yale-New Haven Hospital Radiation Safety Office.

Slides:



Advertisements
Similar presentations
Medication Error Prevention in 2014
Advertisements

Unit 1. Introduction TB Infection Control Training for Managers at the National and Subnational Levels.
Radioiodine Treatment for Benign Thyroid Diseases
WHAT IS BREAST CANCER? Lesson 1:
Demystifying Mercury as the Gold Standard in Healthcare
Written Directives Medical Use of Radioactive Material
RADIATION PROTECTION PRINCIPLES.  Prevent the occurrence of the non-stochastic effect by restricting doses to individuals below the relevant thresholds.
Renal Replacement Therapy (RRT)
Statins in Renal Failure Andrea Fox Sunnybrook Health Science Center May 2010.
Advancements in home hd therapies. Objectives Describe the purpose of hemodialysis Discuss home treatment options including trends and improvements in.
Infection Control in CKD A Culture of Safety Leona Dinnan, RN, CDN.
EDWARD WELSH MARCH Dialysis Adequacy (?).
Chronic Kidney Disease Treatment Options
Release of Patients Treated with I-131: An Update Michael Fuller Team Leader Medical Radiation Safety Team U.S. NRC.
Occupational Safety and Health Administration (OSHA)
Consent for Research Study A study for patients newly diagnosed with advanced glioblastoma (brain cancer): Learning whether a PET scan with F-fluoromisonidazole.
Dialysis Facility Compare Valarie Ashby Co-Managing Director UM-KECC.
MIRD Pamphlet No. 21: A Generalized Schema for Radiopharmaceutical Dosimetry—Standardization of Nomenclature 5/15/2009.
Radioactive Drug Research Committee
Radioiodine Therapy for Graves’ Disease Dr. Khalid B. Makhdomi Nuclear Medicine Physician Aga Khan University Hospital, Nairobi.
~ Make a Difference ~ Become a Nephrology Nurse. Incidence (rate of occurrence) –220 per million in 1992 –334 per million in 2000 Prevalence (number of.
| 1| 1Peer Report: Dialysis Care & Outcomes in the U.S., 2014 | Incidence Peer Report: Dialysis Care & Outcomes in the U.S., 2014 Incidence.
Session 1 (tutorial session): Radiation and Thyroid Cancer Summary Many patients with thyroid cancer were found in the Fukushima Health Management survey.
Endocrine System. SymptomsTreatmentTestsGeneral info Recommendation
Peritoneal Dialysis End Stage Renal Disease Causes and Treatment Methods.
Amany M. Shebl Professor Of Medical-surgical Nursing Dean. Nursing Faculty, Mansoura University, Egypt.
Determination of Effective Half-Life of 131 I in Thyroid Cancer Patients Hoang T. Vu Allen Hrejsa & Alex Markovic *Department of Medical Radiation Physics,
PROSTATE CANCER: RADIATION APPROACHES for advanced disease
DVT Prevention and Anticoagulant Management
Dose Limits for Exposure to Ionizing Radiation
Consent for Research Study A study for patients newly diagnosed with advanced glioblastoma (brain cancer): Learning whether a PET scan with F-fluoromisonidazole.
Verluma Nofetumomab Merpentan (Fragment). Indications For the detection and staging of previously untreated small cell lung cancer. It must be confirmed.
Application of Calibrated Instruments in Medical Facilities MAJ H. Mike Stewart, Jr., MS, CHP April 17, 2009.
Slideshow created by Slideshare user melodiekernahan.
Organization and Implementation of a National Regulatory Program for the Control of Radiation Sources Technical Services.
06/02/2016radiation safety - level 51 Radiation safety level 5 Frits Pleiter.
Chapter 37 Chronic Kidney Disease: The New Epidemic
Careers By: Jackie Cisneros. Registered Nurse  The Entry-level education needed is an associates degree.  No on the job training needed.  No work experience.
Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.
I-131 Patient Release Dose Calculation Principles & Recent Research Lynn McGuire, MS, DABMP Consultant Medical Physicist (ret) UAMS Department of Radiology.
Iodine 131 Medical Uses.
© 2014 Cengage Learning. All Rights Reserved. May not be scanned, copied or duplicated, or posted to a publicly accessible website, in whole or in part.
Anemia in CKD The TREAT Trial Reference Pfeiffer MA. A trial of Darbepoetin alpha in type II diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–2032.
ESTIMATION OF HOSPITAL STAY TIME FOR CA-THYROID PATIENTS TREATED WITH RADIOIODINE-131 By Sudipta Saha 1 Dr. Ashoke kumar paul 2 Dr. M. Shakilur rahman.
Technical Services. Objectives To identify the technical services needed within the infrastructure for an effective implementation of regulatory programme.
Dr.M.shafiee Department of internal medicine Shiraz university of medical sciences.
Chapter 35 – Health Physics
The environmental dose measurements of high dose Iodine-131 treated thyroid cancer patients during hospitalization period Nina TUNÇEL  Department of Physics,
The Caregiver’s Tip Guide
Date of download: 10/7/2017 Copyright © ASME. All rights reserved.
Radiation therapy for Early Stage Prostate Cancer
Radiation related Procedures and in-Utero Effects
Implementation of occupational radiation protection
Hospital Emergency Response Training—Home Training
Factors Affecting Drug Activity
Sharan Packer Specialist Inspector (Radiation)
Quantification and Dosing of Renal Replacement Therapy in Acute Kidney Injury: A Reappraisal Blood Purif 2017;44: DOI: / Fig.
Drug Therapy in Geriatric Patients
Radio Iodine Therapy In Cancer Thyroid
Management of Surgical Smoke Tool Kit
Professor of Nuclear Medicine Cairo University, Egypt
Maria Belgun, L.Dumitriu, A.Goldstein, Mariana Purice, F.Alexiu
The Caregiver’s Tip Guide
OSHA and Bloodborne Pathogens Training for the Medical Office
Nofetumomab Merpentan (Fragment)
Figure 6 Approach to drug management in patients with acute kidney disease (AKD) Figure 6 | Approach to drug management in patients with acute kidney disease.
End-stage renal disease in developing countries
Chapter 5 The Therapeutic Approach to the Patient with a Life-Threatening Illness © 2018 Cengage Learning. All Rights Reserved. May not be scanned,
Nutritional requirements in maintenance hemodialysis
Presentation transcript:

Iodine-131 Therapy and the Dialysis Patient M.J. Bohan and R.L. Richardson Yale-New Haven Hospital Radiation Safety Office

YNHH RSO - HPS 2006 The Problem Thyroid cancer and hyperthyroid patients with renal failure present a number of radiation safety and medical physics challenges Unfortunately, there is not a lot of published sources of information in the literature that address the issues presented by these patients

YNHH RSO - HPS 2006 Health Physics Issues Potential for increased occupational exposures Potential for contamination control and waste disposal issues Early patient release issues - dose to family and the public

YNHH RSO - HPS 2006 Medical Physics Issues How much longer in advance should you recommend iodine dietary restrictions and removal of replacement hormone? Uptake studies may be misinterpreted due to poor systemic washout at hrs Altered excretion kinetics results in greatly increased whole body dose

YNHH RSO - HPS 2006 Case Study Number 1 Female thyroid cancer patient with end stage renal disease on hemodialysis Written directive - Administer 5.6 GBq (152 mCi) Hemodialysis on regular schedule at 48 hrs post administration Patient isolated at hospital for first two dialysis sessions and then was followed as an outpatient for the next week

YNHH RSO - HPS 2006

Patient WB ∞ Dose Estimates Infinite Whole Body Dose Estimates Eff. T 1/2 (days) Dose (Gy) Normal GBq Patient (152 mCi) Hemodialysis Effective Hemodialysis Actual Field Measurements 1.6 MIRD - Pamphlet 11 (1975), I-131 (TB <-- TB), 9.9E-6 rad/uCi-hr

YNHH RSO - HPS 2006 Case Study Number 2 Two years later, same patient, now on peritoneal dialysis Written directive - Administer 11 GBq (296 mCi) Peritoneal dialysis on regular schedule at home Patient isolated dialysis wastes in garage CAPD every 4-6 hours during the day NIPD at night only, for first two days After day 2, CCPD continuously (CAPD - Continuous Ambulatory Peritoneal Dialysis) (NIPD - Nocturnal Intermittent Peritoneal Dialysis) (CCPD - Continuous Cycle Peritoneal Dialysis)

YNHH RSO - HPS 2006

Patient WB ∞ Dose Estimates Infinite Whole Body Dose Estimates Eff. T 1/2 (days) Dose (Gy) Normal - 11 GBq Patient (296 mCi)0.33 Peritoneal Dialysis Effective1.5 Peritoneal Dialysis Actual Field Measurements 1.8 MIRD - Pamphlet 11 (1975), I-131 (TB <-- TB), 9.9E-6 rad/uCi-hr

YNHH RSO - HPS 2006 Case Study Number 3 New male patient on peritoneal dialysis with about 15% of normal renal function Written directive - Administer 1.2 GBq (31.3 mCi) Peritoneal dialysis on regular schedule at home Patient isolated dialysis wastes on porch NIPD at night only

YNHH RSO - HPS 2006 Hours

YNHH RSO - HPS 2006 Patient WB ∞ Dose Estimates Infinite Whole Body Dose Estimates Eff. T 1/2 (days) Dose (Gy) Normal GBq Patient (31.3 mCi) Peritoneal Dialysis Effective Peritoneal Dialysis Actual T 1/2 ≈ 1 day Field Measurements 0.12 MIRD - Pamphlet 11 (1975), I-131 (TB <-- TB), 9.9E-6 rad/uCi-hr

YNHH RSO - HPS 2006 Lessons Learned If you give a dialysis patient a dose which would be appropriate for a normal patient, the whole body dose is extremely high Because the I-131 continues to re-circulate in dialysis patients, you should be able to titrate the administered dose based on the calculated whole body dose and lower their dose without compromising their thyroid uptake If patients have partial kidney function, you should take it into account when calculating the adjusted dose Reducing the administered dose also helps with patient release issues

YNHH RSO - HPS 2006 Consider Changing the Hemodialysis Scheduling Modification of the hemodialysis schedule will dictate the administered dose Schedule 1: 48 hrs post administration, MWF Schedule 2: hr post adm, TThSaMWF Schedule 3: 24 first 3 days then release from isolation with outpatient hemodialysis on Sa, then back to normal MWF

YNHH RSO - HPS 2006 Estimated Whole Body Doses for 100 mCi Rx Normal Pt Gy hr Gy (14%) hr Gy (19%) 24 1st 3days Gy (23%) MonWedFriSunFriSunTueThur

YNHH RSO - HPS 2006 Contamination/Waste Issues Hemodialysis systems are self contained and use copious amounts of water to wash the blood. Residual contamination levels are usually low and easily cleaned up. Cartridges and tubing will retain low levels of activity and should be held for decay

YNHH RSO - HPS 2006 Occupational Dose Issues Hemodialysis nurses must stay close to the dialysis machine and service it periodically You need to train them in time and distance controls to minimize their occupational dose Measured Occupational Doses 5.6 GBq (152 mCi) on in-patient hemodialysis First Dialysis - Nursing Dose 18 mrad Second Dialysis - Nursing Dose 42 mrad

YNHH RSO - HPS 2006 References Jimenez, R.G., et al., Iodine-131Treatment of Thyroid Papillary Carcinoma in patients Undergoing Dialysis for Chronic Renal Failure: A Dosimetric Method, Thyroid, Vol. 11, NO. 11, 2001 Mars, D.R., et al, Iodine Retention and Thyroid Dysfunction in Patients on Hemodialysis and Continuous Ambulatory Peritoneal Dialysis, Am. J. Kidney Dis., June 1986, 7(6):471-6) Magne, N., et al, Disposition of Radioiodine 131-I therapy for Thyroid Carcinoma in a Patient with Severely Impared Renal Function on Chronic Dialysis: A Case Report, Jpn. J. Clininal Oncology 2002; 32(6) Kaptein, E.M., Radioiodine Dosimetry in Patients with End-stage Renal Disease Receiving Continuous Ambulatory Peritoneal Dialysis Therapy, J Clin Endocrinol Metab Sep;85(9): Sisson, J.C., Practical Dosimetry of 131-I Patients with Thyroid Carcinoma, Cancer Biotherapy & Radiopharmaceuticals, Vol. 17, No. 1, 2002 Thomas, S.R., Options for Radionuclide Therapy: From Fixed Activity to Patient-Specific Treatment Planning, Cancer Biotherapy & Radiopharmaceuticals, Vol. 17, No. 1, 2002 Kaptein, E.M., Radioiodine Dosimetry in Patients with End-Stage Renal Disease Receiving Continuous Ambulatory Peritoneal Dialysis Therapy, The Journal of Clinical Endocrinology & Metabolism, Vol. 85, No. 9, 2000